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ABSTRACT
Expression of Glycogen Synthase Kinase-3 (GSK-3) is elevated in prostate cancer 
and its inhibition reduces prostate cancer cell proliferation, in part by reducing 
androgen receptor (AR) signaling. However, GSK-3 inhibition can also activate signals 
that promote cell proliferation and survival, which may preclude the use of GSK-3 
inhibitors in the clinic. To identify such signals in prostate cancer, we screened for 
changes in transcription factor target DNA binding activity in GSK-3-silenced cells. 
Among the alterations was a reduction in AR DNA target binding, as predicted from 
previous studies, and an increase in NFκB DNA target binding. Consistent with the 
latter, gene silencing of GSK-3 or inhibition using the GSK-3 inhibitor CHIR99021 
increased basal NFκB transcriptional activity. Activation of NFκB was accompanied by 
an increase in the level of the NFκB family member RelB. Conversely, silencing RelB 
reduced activation of NFκB by CHIR99021. Furthermore, the reduction of prostate 
cancer cell proliferation by CHIR99021 was potentiated by inhibition of NFκB signaling 
using the IKK inhibitor PS1145. Finally, stratification of human prostate tumor gene 
expression data for GSK3 revealed an inverse correlation between NFκB-dependent 
and androgen-dependent gene expression, consistent with the results from the 
transcription factor target DNA binding screen. In addition, there was a correlation 
between expression of androgen-repressed NFκB target genes and reduced survival 
of patients with metastatic prostate cancer. These findings highlight an association 
between GSK-3/AR and NFκB signaling and its potential clinical importance in 
metastatic prostate cancer.
INTRODUCTION
The protein kinase Glycogen synthase kinase-3 
(GSK-3) is up-regulated in many cancers, including 
prostate cancer (PCa) [1–3] and GSK-3 inhibitors reduce 
prostate tumor growth in vitro [4, 5] and in vivo [6]. 
PCa initiation and progression are uniquely dependent 
on the androgen receptor (AR) [7]. AR transcriptional 
activity is regulated by co-activator and co-repressor 
proteins and by posttranslational modifications, such as 
phosphorylation by kinases [4, 8–11], including GSK-3, 
which is important for AR stability, nuclear localization 
and transcriptional activity [4, 5, 12]. The mechanism 
of action of GSK-3 is however complex and context-
dependent, since its overexpression in some cell types 
inhibits AR [10, 11] and there are instances where  GSK-3 
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inhibitors reduce proliferation of AR-negative PCa cells 
[13, 14]. In addition, GSK-3 regulates other signals, 
such as those mediated by Wnt and NFκB, which are 
themselves linked [15]. Adding further complexity, there 
are two GSK-3 isoforms, GSK-3α and GSK-3β that have 
different expression profiles in PCa [1]. Knockout studies 
have shown that the two isoforms generally compensate 
for one another [16]. However, there are examples where 
a single isoform has a unique or predominant function 
[17, 18]. This is the case in PCa, where GSK-3α is more 
important for maintaining AR transcriptional activity 
and silencing GSK-3β but not GSK-3α reduces PKB 
phosphorylation [1].
In order to identify isoform-specific GSK-3 targets 
in PCa, we screened for transcription factors whose 
binding to cognate DNA target sequences is altered upon 
GSK-3 silencing. We observed reduced binding to an AR 
target binding site upon silencing GSK-3α, consistent 
with our earlier study [1], and increased binding to an 
NFκB target-binding site in cells chronically silenced for 
GSK-3β. Further analyses using PCa cell lines and tumor 
array data revealed a link between GSK-3 expression and 
an inverse correlation between AR and NFκB signaling 
pathways. GSK-3 has previously been linked to NFκB 
activation [19] and there are a variety of reports on the 
mechanisms involved. For example, GSK-3 can inhibit 
p65 transcriptional activity [20], increase p105 stability 
[21], suppress chromatin accessibility [22] and inhibit 
IKK phosphorylation of IκB [23]. On the other hand, there 
are many instances where targeted deletion of GSK-3β 
inhibits NFκB activity [24–26]. The conclusion from these 
apparently conflicting studies is that GSK-3 regulation 
of NFκB is highly context-dependent and will only be 
understood by carrying out experiments using the cells 
and tissues of interest. The studies described in this report 
find that acute gene silencing and chemical inhibition 
of GSK-3 increase basal NFκB activity in PCa, and that 
combined inhibition of GSK-3 and NFκB signaling is 
more effective than inhibition of each alone for reducing 
PCa cell proliferation.
RESULTS
A screen for transcription factor targets of 
GSK-3 in PCa cells identifies unique and 
common targets of GSK-3α and GSK-3β
In order to identify isoform-specific GSK-3 targets 
in PCa, we screened for transcription factors whose 
binding to cognate DNA target sequences is altered upon 
GSK-3 silencing in 22Rv1 PCa cells. Since we previously 
found differences between the effects of acute and chronic 
silencing of GSK-3 on AR activity [1], experiments 
were carried out using both conditions. In the acute 
silencing experiments, we used nuclear extracts from 
cells transiently transfected with shRNAs specific for 
GSK-3α or GSK-3β. Acute GSK-3α silencing reduced 
the binding activity of AR to its DNA target element 
(Figures 1A and B), consistent with our previous study [1]. 
Also in keeping with these results, silencing of GSK-3α 
but not of GSK-3β reduced expression of the AR target 
gene TMEPA1 [27], but not of AR itself (Figure 1C). In 
addition, silencing GSK-3α increased binding activity of 
activator protein 2 (AP-2) (Figure 1A), without affecting 
expression of TFAP2A (Figure 1C), the major AP-2 
family member expressed in 22Rv1 cells, and silencing 
GSK-3α and, to a lesser extent, GSK-3β increased binding 
activity of the glucocorticoid receptor (GR) (Figures 1A 
and B). We next carried out protein/DNA array screens 
using extracts from 22Rv1 cell clones stably silenced for 
either GSK-3α or GSK-3β. In contrast to the results from 
acute silencing, binding to AR target DNA was slightly 
increased in cells stably silenced for GSK-3α (Figures 1D 
and F). In addition, the changes in AP-2 and GR binding 
activities observed upon acute silencing of GSK-3α were 
not seen in stably silenced cells, suggesting that several 
changes induced upon acute silencing of GSK-3 are not 
maintained in stably silenced cell lines. Several other spots 
were reproducibly altered with stable GSK-3α silencing, 
namely an increase in binding to the Sp1 binding site 
(row 11 columns 1/2), the Stat5/6 binding site (columns 
13/14) and the Pbx1 binding site (row 7 columns 15/16), 
also observed upon acute silencing of GSK-3α. To address 
the possibility that stable inhibition of GSK-3 leads to 
selection for prostate cancer stem/progenitor-like cells, 
as was recently reported for PC3 cells [28], we measured 
the expression levels of three genes expressed in 22Rv1-
derived stem/progenitor cells, SOX2, NANOG and BCRP 
[29], in the 22Rv1-derived cell clones. This revealed 
small reductions in expression of SOX2 in both GSK- 
3-isoform silenced cell lines, a small increase in NANOG 
expression in the GSK-3α-silenced cell line and no 
change in expression of BCRP (Figure 1E). These results 
suggest that stable inhibition of GSK-3 isoforms does not 
lead to selection for prostate cancer stem/progenitor-like 
cells. In addition, we observed increased binding to the 
NFκB target DNA sequence in cells stably silenced for 
GSK-3β (Figures 1D, F), and, consistent with this, NFκB-
dependent transcription was increased in cell lines stably 
silenced for GSK-3β (Figure 1G).
GSK-3 inhibition activates NFκB 
independently of β-catenin and AR
The observation that stable but not acute silencing of 
GSK-3β increased NFκB activity prompted us to determine 
the effects of acute silencing on NFκB-dependent 
transcription. Acute silencing of single GSK-3 isoforms 
did not affect NFκB transcriptional activity (Figure 2A), 
consistent with no change in NFκB target DNA binding 
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Figure 1: A screen for transcription factor targets of GSK-3 in PCa cells identifies AR and NFkB as targets of GSK-
3α and GSK-3β, respectively. (A) Scanned images of transcription factor DNA binding site arrays probed with nuclear extracts 
from 22Rv1 cells transiently transfected with the indicated shRNAs. The grey boxes highlight relevant transcription factor binding sites; 
changes in signal, compared with control shRNA-transfected cells, are indicated in black (increased binding to AP-2 and GR binding sites) 
and white (reduced binding to AR binding site). (B) Average signals for the indicated binding sites from two independent experiments in 
duplicate, relative to control shRNA; * p < 0.05, compared to control shRNA. (C) 22Rv1 cells transfected with indicated shRNA plasmids 
were selected with puromycin for 72 h and the expression of GSK3A, GSK3B, TMEPA1, AR and TFAP2A mRNAs determined by q-PCR; 
* p < 0.05 compared to control shRNA (Ctrl sh); n = 3. (D) Scanned images of representative transcription factor DNA binding site arrays 
probed with nuclear extracts from 22Rv1 cell clones expressing control, GSK-3α (clone 3) or GSK-3β (clone 18) shRNAs. Grey boxes 
highlight relevant transcription factor binding sites; black box shows increased signal at the NFkB binding site. (E) Analysis for the mRNA 
expression levels of SOX2, NANOG, BCRP1, GSK3A and GSK3B in 22Rv1 cell clones expressing control, GSK-3α (clone 3) or GSK-3β 
(clone 18) shRNAs was determined by q-PCR; * p < 0.05 compared to control shRNA (Ctrl sh); n = 3. (F) Average signals for the indicated 
binding sites for two independent cell clones for each in duplicate, relative to control cells; * p < 0.05, compared to control. (G) Gene 
reporter assays using extracts from 22Rv1 cell clones as in D. Basal NFκB activity was measured using NFκB-luciferase and AR activity 
was measured using MMTV-luciferase in cells cultured in charcoal-stripped medium with 10−8 M DHT. Renilla was used to normalize for 
transfection efficiency. Graphs show luciferase/renilla values, relative to control cells; * p < 0.05, compared to control; n = 2.
Oncotarget8176www.impactjournals.com/oncotarget
Figure 2: GSK-3 inhibition activates NFκB independently of β-catenin and AR. (A) Gene reporter assays using extracts from 
22Rv1 cells transfected with control shRNA (Ctrl sh) or shRNAs targeting GSK-3α (GSK3a sh), GSK-3β (GSK3b sh) or both GSK3a/b 
sh), and plasmids encoding NFκB-luciferase and renilla (pRL-tk), and treated with TNF (20 nM) or vehicle for 6 h. Graph shows luciferase/
renilla ratios 18 h after transfection normalized to Ctrl sh; * p < 0.05 vs. Ctrl sh; n = 4. (B) Gene reporter assays using extracts from 22Rv1 
cells transfected with plasmid encoding β-catenin or empty vector, Super8xTOPFlash or Super8xFOPFlash and renilla. Graph shows 
luciferase/renilla ratios normalized to vector; * p < 0.01 vs. vector. (C) Gene reporter assays using extracts from 22Rv1 cells transfected 
with the indicated amounts of plasmid encoding β-catenin (total amount brought to 200 ng with empty vector), and plasmids encoding 
NFκB-luciferase and renilla. Graph shows luciferase/renilla ratios, normalized to 0 ng β-catenin plasmid; * p < 0.05 vs. vector. (D) Gene 
reporter assays using extracts from 22Rv1 cells and PC3 cells transfected with NFκB-Luc and renilla. After transfection, cells were cultured 
for 18 h in phenol red-free medium containing charcoal-stripped serum with or without 10 nM DHT and then treated with 20 nM TNF for 
6 h before measuring luciferase activities. Graph shows luciferase/renilla ratios; TNF-induced activity is set to 100% in each cell line; * 
p < 0.05; n = 3 (22Rv1), n = 2 (PC3). (E) Gene reporter assays using extracts from 22Rv1 cells transfected with MMTV-luc and renilla, 
treated with carrier (DMSO) or the AR antagonist 10 uM MDV3100 (MDV) and AR activity determined as in Figure 1F; *p < 0.05 vs. 
control; n = 2. (F) Gene reporter assays using extracts from 22Rv1 cells transfected with plasmids encoding NFκB-luciferase and renilla 
and treated with carrier (DMSO), 5 uM CHIR99021 (CHIR) and 10 uM MDV3100 (MDV), as indicated. Graph shows luciferase/renilla 
ratios normalized to DMSO; * p < 0.05 vs. DMSO; n = 2.
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being observed (Figure 1A and data not shown). However, 
silencing of both GSK-3 isoforms together modestly but 
significantly increased basal NFκB transcriptional activity 
(Figure 2A). In addition, NFκB transcriptional activity was 
increased by treatment of cells with the specific GSK-3 
inhibitor CHIR99021 [30] (see Figure 2F). In summary, 
chronic silencing of GSK-3β and acute inhibition of 
GSK-3α/β led to activation of NFκB, as detected by 
increased DNA target binding and transcriptional activity. 
We therefore decided to explore the effects of GSK-3 
inhibition on NFκB signaling in more detail.
Since silencing of both GSK-3 isoforms together 
also activates Wnt/β-catenin signaling in 22Rv1 cells [1], 
we wished to determine if stabilization of β-catenin was 
responsible for the observed activation of NFκB. Cells were 
transfected with a plasmid encoding stabilized β-catenin, 
which increased β-catenin/Tcf-dependent transcription 
as expected (Figure 2B). β-catenin inhibited NFκB-
dependent transcription (Figure 2C), suggesting that the 
effect of GSK-3 inhibition on NFκB is not mediated by 
β-catenin. In addition to increasing basal NFκB activity, 
GSK-3 inhibitors reduce AR-dependent transcription [4]. 
Given previous reports that androgens inhibit NFκB [31, 
32], we hypothesized that GSK-3 inhibition leads to NFκB 
activation by inhibiting AR. To test this possibility, we first 
examined the effect of AR activation on NFκB activation 
by Tumor Necrosis Factor (TNF). Cells were stimulated 
with TNF in the presence or absence of the AR ligand DHT. 
DHT treatment reduced TNF activation of NFκB in 22Rv1 
cells (Figure 2D) and, to a lesser extent, in LNCaP cells 
(data not shown), but not in PC3 cells, which do not express 
AR (Figure 2D). These results suggest that AR could play a 
role in the activation of NFκB upon GSK-3 inhibition. To 
determine the impact of AR on GSK-3 inhibitor-mediated 
activation of NFκB, gene reporter assays were carried 
out in the presence of the AR antagonist MDV3100. As 
expected, MDV3100 inhibited AR transcriptional activity 
(Figure 2E). However, it did not affect NFκB activation 
by CHIR99021 (Figure 2F), suggesting that the effects of 
GSK-3 on NFκB are not mediated via AR.
Inhibition of GSK-3 activates NFκB via RelB
NFκB consists of a family of transcription factors 
whose subunits p65 (RelA), RelB, c-Rel, and p50 and 
p52, generated from the precursors p105 and p100, 
respectively, form dimers that regulate gene expression. 
IκB proteins sequester NFκB dimers in the cytoplasm and 
activation of IκB kinase (IKK) results in IκB degradation 
and the release of NFκB [33]. To determine if NFκB 
activation upon GSK-3 inhibition involves IκB, we used 
the Gal4-p65/Gal4-luc system [34], in which a fusion 
protein formed by the Gal4 DNA-binding domain and 
the p65 transactivation domain drives expression of Gal4-
responsive luciferase independently of IκB. Treatment 
of 22Rv1 cells with CHIR99021 or the unrelated GSK-3 
inhibitor BIO-Acetoxime (BIO) increased p65-Gal4 
activity (Figure 3A), suggesting that GSK-3 inhibition 
activates NFκB signaling independently of IκB.
To determine if the effects of GSK-3 inhibition 
involved changes in NFκB family proteins, we next 
examined their expression levels by western blotting. 
Silencing of both GSK-3 isoforms together did not 
significantly affect most NFκB family members, although 
there was a trend for a reduction in the p100/p52 ratio. 
However, silencing GSK-3 did result in a small but 
significant increase in RelB (Figure 3B). In support of the 
gene silencing results, CHIR99021 also increased RelB 
levels (Figure 3C). Since GSK-3 regulates the subcellular 
localization of many proteins, we examined the effects of 
GSK-3 silencing on the localization of p100/52 and p65 
(RelB could not be readily detected using the available 
antibodies). P100/52 was found mostly in the nucleus 
(Figure 3D) and p65 mostly in the cytoplasm (Figure 3E), 
and neither one was affected by GSK-3 silencing. Changes in 
p65 were also not detected in cells treated with CHIR99021 
(Figure 3F). In contrast, treatment of 22Rv1 cells with TNF 
induced nuclear translocation of p65 (Figure 3G). Together, 
these results raise the possibility that activation of NFκB 
upon inhibition of GSK-3 results from an increase in RelB. 
To investigate the role of RelB, gene reporter assays were 
carried out in 22Rv1 cells silenced for p65, RelB and c-Rel 
[35] (Figure 3H). Silencing RelB and, to a lesser extent p65, 
but not c-Rel, reduced CHIR99021-mediated activation of 
NFκB (Figure 3I), indicating that RelB plays a predominant 
role in the response to CHIR99021.
Inhibition of NFκB potentiates the inhibitory 
effect of CHIR99021 on PCa cell proliferation
Since activation of NFκB promotes cancer cell 
survival, we hypothesized that combined inhibition of 
GSK-3 and NFκB would inhibit proliferation in PCa 
cells. To test this possibility, we treated 22Rv1 cells with 
CHIR99021 to inhibit GSK-3 and PS1145 to inhibit NFκB 
signaling. As expected, given the low basal NFκB activity 
in 22Rv1 cells, PS1145 alone had no significant effect on 
cell number (Figure 4A). However, PS1145 potentiated 
the effects of CHIR99021, consistent with our hypothesis. 
The activities of the inhibitors were confirmed using gene 
reporter assays: CHIR99021 increased β-catenin activity 
(Figure 4B) and PS1145 inhibited TNF-induced NFκB 
activation (Figure 4C). Since GSK-3 inhibition represses 
AR signaling, we also tested the effects of combined 
inhibition of GSK-3, NFκB and AR on cell proliferation 
using MDV3100. In these experiments we used a dose of 
CHIR99021 that had no significant effect on proliferation 
when used alone (Figure 4D). As expected, MDV3100 
reduced 22Rv1 cell proliferation and this effect was 
slightly enhanced by CHIR99021. Importantly, combined 
treatment of cells with MDV3100, CHIR99021 and 
PS1145 further reduced cell number (Figure 4D). We also 
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Figure 3: Inhibition of GSK-3 activates NFκB via RelB. (A) Gene reporter assays using extracts from 22Rv1 cells transfected with 
plasmids encoding p65-Gal4 Gal4-Luc, renilla and treated with vehicle (DMSO) or 5 uM CHIR99021 (CHIR) or 2.5 uM BIO-Acetoxime 
(BIO). Graph shows luciferase/renilla ratios normalized to DMSO; * p < 0.05 vs. DMSO; n = 2. (B) Western blots of extracts from 22Rv1 
cells transfected with control shRNA (c) or shRNAs targeting GSK-3α (α), GSK-3β (β) or both isoforms (α/β), selected with puromycin 
for 72 h and probed for the indicated NFκB family proteins and HSP60 and GAPDH as loading controls. Numbers below the GAPDH 
blot indicate relative RelB signal normalized to GAPDH. Densitometry analysis (ImageJ) from 3 experiments indicated that silencing 
both GSK-3 isoforms together increased RelB 1.6 to 2.1-fold, compared to control shRNA (p < 0.05). (C) Western blots of extracts from 
22Rv1 cells treated with 2.5 uM CHIR99021 (CHIR) or vehicle (DMSO) for 16 h were probed for RelB and GAPDH as a loading control. 
Densitometry analysis from 3 experiments indicated that RelB was 1.4 to 2.3-fold higher in CHIR99021-treated cells than in DMSO-treated 
cells (p < 0.05). (D, E) Immunostaining for GSK-3α and GSK-3β (red) and p100/p52 (D) or p65 (E) (white) in 22Rv1 cells transfected 
with shRNAs to silence both GSK-3 isoforms and GFP plasmid (green) to visualize transfected cells. DAPI staining of nuclei is shown in 
blue. Arrows indicate cells silenced for GSK-3; scale bars 25 μm. (F) Immunostaining for p65 (green) in 22Rv1 cells treated with vehicle 
(DMSO) or CHIR99021 (CHIR) for 16 h. DAPI staining of nuclei is shown in blue; scale bar 25 μm. (G) Immunostaining for p65 (green) 
in 22Rv1 cells with vehicle (Ctrl) or TNF for 3 h. DAPI staining of nuclei is shown in blue; scale bar 62.5 μm. (H) Western blots of extracts 
from 22Rv1 cells transfected with control (left) or the indicated shRNA plasmid (right), selected with puromycin for 72 h and probed for 
p65, RelB and c-Rel; GAPDH was used as a loading control (blot shown is for RelB shRNA). (I) Gene reporter assays using extracts 
from 22Rv1 cells transfected with control (Ctrl), p65, RelB and c-Rel shRNAs, selected with puromycin for 72 h, then transfected with 
NFκB-luciferase and renilla and treated with DMSO or CHIR99021 at 2.5 uM and 5 uM. Graph shows luciferase/renilla ratios normalized 
to DMSO in Ctrl cells; * p < 0.05 vs. Ctrl sh at the same dose of CHIR99021; n = 2.
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Figure 4: Inhibition of NFκB potentiates the inhibitory effect of CHIR99021 on PCa cell proliferation. (A) Left: 
representative experiment showing crystal violet staining of 22Rv1 cells cultured for 1 week with DMSO, 10 uM PS1145 and/or the 
indicated concentrations of CHIR99021 (CHIR). Right: absorbance (540 nm) of solubilized crystal violet was used to calculate relative cell 
number; *p < 0.01. (B) β-catenin/Tcf-dependent transcriptional activity in 22Rv1 cells treated with carrier (DMSO) or 5 μM CHIR99021 
(CHIR) was determined by gene reporter assay using Super8xTOPFlash normalized to renilla. (C) NFκB-dependent transcriptional activity 
in 22Rv1 cells treated with carrier or TNF and 10 uM PS1145 (PS) as determined by gene reporter assay using NFκB-luciferase normalized 
to renilla; *p < 0.01 vs. DMSO. (D) Quantitation of crystal violet assays showing relative cell number for 22Rv1 cells cultured for 1 week 
in the presence of carrier (DMSO) -/+ 1 uM CHIR99021 (CHIR), 10 uM MDV3310 (MDV) and 10 uM PS1145 (PS); p < 0.05 versus 
DMSO (*) and versus MDV (**). (E) Quantitation of crystal violet assays showing relative cell number for PC3 cells cultured for 1 week 
in the presence of DMSO, 10 uM PS1145 and/or the indicated concentrations of CHIR99021 (CHIR); *p < 0.01.
examined the effects of combined inhibition of GSK-3 
and NFκB in PC3 cells, which do not express AR and 
have constitutively high NFκB activity. Single treatments 
with PS1145 and CHIR99021 significantly reduced PC3 
cell number, and the combination of both inhibitors had 
an additive effect (Figure 4E). These results suggest that 
combined inhibition of GSK-3 and NFκB may also be an 
effective for androgen-independent PCa.
GSK3 expression is associated with an inverse 
correlation between AR and NFκB signaling in 
prostate tumors
The observed effects of combined inhibition of 
GSK-3, NFκB and AR prompted us to look for possible 
links among these signaling pathways in human tumors. 
To this end, we carried out gene set enrichment analysis 
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(GSEA) [36] of human tumors from a previously 
published database [37]. Tumors were first sorted based 
on the summed Z-score of the expression levels of a set 
of genes that is regulated by androgen signaling (AR 
signature) [38]. Tumors with the highest summed Z-scores 
were classified as “high AR signature” tumors and those 
with the lowest values were classified “low AR signature” 
tumors (Figure 5A). GSEA was then used to examine 
NFκB pathway activity within these two groups using an 
NFκB target gene signature [39]. The NFκB target gene 
signature was significantly diminished in tumors with 
the high AR signature, supporting the hypothesis that 
AR signaling inversely correlates with NFκB signaling 
(Figure 5B). This was also observed in an independent 
tumor dataset [40] (Figure 5C). We next examined NFκB 
target gene expression levels in tumors with high or low 
expression of GSK3A and GSK3B. Tumors with a positive 
Z-score (compared to normal prostates) of both GSK-3 
isoform mRNAs were classified as “high GSK-3”, and 
tumors with a negative score for both isoforms were 
classified as “low GSK-3”. Although this classification 
only reflects GSK-3 mRNA expression (above or below 
that in normal prostate) and not kinase activity, it revealed 
that tumors with low GSK-3 expression were enriched for 
androgen-repressed NFκB target genes (Figures 5D, E). 
Finally, in order to determine whether expression of the 
androgen-repressed NFκB target genes identified has 
prognostic potential in prostate cancer, we analyzed a 
publicly available patient data set with follow-up data from 
the cBio Cancer Genomics portal [41]. This revealed that 
high expression of androgen-repressed NFκB target genes 
is significantly correlated with reduced survival in patients 
with metastatic prostate cancer (Figure 6). Together, these 
findings highlight an inverse correlation between GSK-3/
AR and NFκB signaling in patient tumors with potential 
clinical importance in metastatic prostate cancer.
DISCUSSION
The involvement of GSK-3 in cancer is complex, 
with evidence supporting roles for this kinase as a tumor 
suppressor and a tumor promoter. Further complexity 
arises from the existence of multiple GSK-3 isoforms 
with differences in expression, subcellular localization 
and substrate preference. GSK-3 inhibitors are currently 
in clinical trials for the treatment of metastatic pancreatic 
cancer [42], and have the potential to be used to treat 
several other types of cancer, including PCa. Given the 
complex responses to GSK-3 in different cell types, 
it will be important to identify tumor-specific GSK-3 
targets as biomarkers for effective treatment. In addition, 
it is essential to identify targets that may have undesired 
effects on tumor cell survival or proliferation. The present 
study reveals that inhibition of GSK-3 in PCa cells leads 
to activation of NFκB, and that this reduces the impact of 
GSK-3 inhibition on cell proliferation. These observations 
suggest that combined inhibition of GSK-3 and NFκB 
may be required for effective inhibition of prostate tumor 
growth.
In this report we have focused on NFkB and its 
relationship with AR. However, our analysis of GSK-3 
targets revealed additional potential targets and, in 
addition, differences between stably silenced and 
transiently silenced cells that will require further analysis. 
We noted in our earlier study [1] that while there were no 
significant differences in growth rates of the stable cell 
lines in short-term (72 h) proliferation assays, cell lines 
with reduced levels of either GSK-3α or GSK-3β formed 
fewer colonies than control cells in colony formation 
assays. Moreover, when colony formation assays were 
conducted in hormone-depleted medium, GSK-3α-
silenced cell lines formed similar numbers of colonies 
as control cells, whereas GSK-3β-silenced cells formed 
fewer colonies. Those results suggested that chronic 
silencing of GSK-3α has an impact on hormone-dependent 
growth, while chronic silencing of GSK-3β affects both 
hormone-dependent and hormone-independent growth 
[1]. However, the mechanisms that underlie the different 
transcriptional consequences of short-term versus long-
term GSK-3 inhibition are not known. One possibility 
is that stable inhibition of GSK-3 isoforms leads to 
selection for different cell subsets or types, or changes 
the proportions of precursor cells in the population. 
Consistent with this possibility, small molecule inhibition 
of GSK-3 was recently reported to deplete the population 
of prostate cancer stem/progenitor-like cells in PC3 and 
PC3M cells, as measured by the proportion of ALDHHIGH 
cells and reduced expression of stem/progenitor markers 
including NANOG and OCT4 [28]. However, this was not 
observed in LNCaP C4-2 and DU145 cells. Our analysis 
of 22Rv1 stem/progenitor cell marker gene expression 
revealed a small increase in NANOG and reduction in 
SOX2 in GSK-3α-silenced cells (Figure 1E), inconsistent 
with selection for prostate cancer stem/progenitor-like 
cells. Nevertheless, it is interesting to note that treatment 
of PC3M cells with a small molecule inhibitor of GSK-3 
also had opposite effects on expression of NANOG and 
SOX2. Further studies will be required to determine if 
changes such as these reflect a change in the proportion of 
a specific population of progenitor cells.
As outlined in the Introduction, GSK-3 has 
previously been linked to NFκB activation and the 
mechanisms involved may be highly context-dependent. 
Our studies found that acute gene silencing and chemical 
inhibition of GSK-3 increase basal NFκB activity. 
Inhibition of GSK-3 in serum-starved cells has previously 
been reported to activate NFκB via degradation of IκB 
and nuclear translocation of p65 [19, 43]. This does 
not appear to be the mechanism in PCa cells, since p65 
remained in the cytoplasm in CHIR99021-treated cells 
(Figure 3F) and inhibition of GSK-3 increased p65-Gal4 
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Figure 5: GSK3 expression is associated with an inverse correlation between AR and NFκB signaling in prostate 
tumors. (A) Heatmap showing the expression of AR target genes in tumors with elevated expression (highest summed Z-score) versus 
tumors with reduced expression (lowest summed Z-score) of the indicated genes; dataset: Becic-00235 in the CaArray database. (B–E) 
Gene Set Enrichment Analysis (GSEA) of NFκB target genes in human tumors (B, C) Heatmap and enrichment score of the NFκB gene 
signature [39] in tumors with elevated expression of AR target genes (highest summed Z-score; high AR signature) versus tumors with 
reduced expression (lowest summed Z-score; low AR signature); datasets Becic-00235 (B) and GSE21034 (GEO) (C); p < 0.01. (D, E) 
Heatmap and enrichment score of NFκB-target genes with reduced expression in tumors with elevated androgen signaling (AR-repressed 
NFκB-targets) in tumors with elevated expression (Z-score > 0.5; GSK-3 High) versus reduced expression (z-score < 0.5; GSK-3 Low) of 
both GSK-3 isoforms; datasets Becic-00235 (D) and GSE21034 (GEO) (E); p < 0.01.
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activity (Figure 3A), which suggests activation takes 
place downstream of IKK/IκB. Instead, we observed 
increased levels of RelB upon GSK-3 inhibition, as has 
been reported in Jurkat cells, where GSK-3 was found 
to promote RelB degradation [44]. The importance of 
RelB in PCa is underlined by its increased expression in 
high Gleason score tumors [45], and by a study in which 
gene silencing of RelB reduced PCa cell tumorigenicity 
[46]. Although we did not detect changes in p65 levels 
or nuclear localization upon GSK-3 inhibition, the results 
of the p65-Gal4 reporter assays (Figure 3A) and the gene 
silencing experiments (Figure 3I) suggest that p65 may 
play an indirect role in GSK-3 inhibitor-induced NFκB 
activation. Such a role could result from the known cross-
regulation of p65 and RelB signaling, which takes place at 
several levels [33].
Analysis of AR and NFκB transcriptional activities 
in PCa cell lines suggests an inverse association that also 
correlates with GSK-3. One possibility is that a reduction in 
GSK-3 signaling activity, for example resulting from loss 
of PTEN, leads to activation of NFκB, which then inhibits 
AR signaling. This would be inconsistent with the view that 
NFκB increases AR expression and/or activity [47–49], 
although there is also evidence that NFκB inhibits AR in 
androgen-dependent PCa [50]. A second possibility is that 
inhibition of GSK-3 reduces AR activity, which then leads 
to NFκB activation. This would be consistent with our 
observation and other reports that activation of AR inhibits 
NFκB [31, 32]. However, the AR antagonist MDV3100 
did not increase basal NFκB activity or potentiate GSK-3 
inhibitor-mediated NFκB activation (Figure 2F), suggesting 
that this not the case in 22Rv1 cells. A third possibility is 
that GSK-3 independently regulates AR and NFκB and 
their relative activities are determined by the activation 
state of GSK-3. This possibility would be consistent 
with the gene expression data, which showed an inverse 
correlation between androgen- and NFκB-dependent 
target gene expression in PCa that correlates with GSK-3 
mRNA expression. In addition, we observed a correlation 
of ‘androgen-repressed NFκB target’ gene expression and 
reduced survival of patients with metastatic prostate cancer 
(Figure 6). While this manuscript was in review, a study 
Figure 6: Inverse correlation of survival of patients with metastatic prostate cancer and expression of AR-repressed 
NFκB-targets. Kaplan Meier plots were obtained from the cBio Cancer Genomics portal, analyzing the Michigan metastatic prostate 
adenocarcinoma dataset (ref [41]) and the AR-repressed NFκB-targets from Figure 5 (CSF1, IL6, PTAFR, BCL3, CCR7, CCL5, RELB, 
CXCL5, MMP9, PLAU, HMOX1, CCL11, CR2, CD80, TNFRSF9, IL15RA, IFNB1, CCL15, BDKRB1, IL2RA, LTB, APOC3, IL13, IL1RN, 
PTX3, CRP, IL1A, CSF2 and IL9). Statistical significance of the whole sample was determined with the Log Rank test at 100 months 
p= 0.0327; Chi-Square test = 4.6 on 1 degree of freedom.
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was published of the effects of increased NFκB activity and 
androgen-depletion on gene expression in non-tumorigenic 
mouse prostates. This led to the identification of a gene 
expression signature that predicted disease-specific survival 
and distant metastases-free survival in patients with PCa 
[51]. Intriguingly, the genes in that signature do not show 
any overlap with the genes we analyzed here. Further 
studies will be required to establish if these tumor signatures 
arise from specific misregulation of NFκB- and androgen-
dependent signaling in a subset of tumor cells, or from 
tumors of different cellular compositions.
Our results suggest that combining GSK-3, AR and 
NFκB inhibitors will provide a more effective therapy than 
single agents for the treatment of some prostate tumors. 
A combination of GSK-3 and NFκB inhibitors was 
recently proposed for treatment of osteosarcoma [52]. 
In this example, however, inhibition of GSK-3 reduced 
NFκB activity, once again underlining the context-
dependent nature of the link between GSK-3 and NFκB 
signaling. Importantly, since silencing GSK-3α alone 
reduces AR activity without activating NFκB, our results 
support the case for the development and sequential use 
of isoform-specific GSK-3 inhibitors [53] to treat different 
stages of PCa.
METHODS
Cell culture and proliferation assays
22Rv1 cells (ATCC) were cultured in RPMI 1640/
DMEM (1:1) (Invitrogen) supplemented with 20% 
FCS and antibiotics (100 U/ml penicillin, 100 μg/ml 
streptomycin) at 37ºC and 5% CO2. LNCaP and PC3 
cells (ATCC) were cultured in RPMI 1640 supplemented 
with 10% FCS and antibiotics. Cells were passaged when 
they reached 70–80% confluence at 1:5–6 using 0.05% 
trypsin. For proliferation assays, cells were seeded at a 
density of 1,000 cells/cm2 in triplicate in 12-well plates 
and inhibitors or an equal volume of carrier were added 
the next day. Media were replaced and fresh inhibitors 
added every other day for 7 days. Cells were then rinsed 
with PBS, stained with crystal violet, rinsed again, air-
dried and images acquired. In some experiments, crystal 
violet was subsequently solubilized in 10% acetic acid and 
absorbance measured at 590 nm. The GSK-3 inhibitors 
CHIR99021 (Axon Medchem and Calbiochem) and BIO-
acetoxime (Merck), the IKK inhibitor PS1145 (Sigma) 
and the AR inhibitor MDV3100 (Selleck Chemicals LLC) 
were all dissolved in DMSO. TNF (R&D) was dissolved 
in PBS + 0.1% BSA and DHT (Sigma) in ethanol.
RNA analysis
Reverse transcription was performed on 1 ug of total 
RNA using M-MLV Reverse Transcriptase and RNase 
OUT Ribonuclease Inhibitor (Invitrogen), according 
to manufacturer’s instructions. Quantitative-PCR was 
performed using PerfeCTa Sybr Green Supermix, 
Low Rox (Quanta, Barcelona, Spain) in a Viia7 Real-
Time PCR System (Applied Biosystems). The primer 
sequences were previously described [54–56], apart from 
GSK3A AGGTCCCCAGCGGGCACTAC, 
GGGTAGGTGTGGCATCGGTCG; GSK3B 
GTCCTGGGAACTCCAACAAGGG, 
GTGAAATGTCCTGTTCCTGAC; and 
TFAP2A ACGTTACCCTGCTCACATCAC, 
CAGGAAATTCGGTTTCGCACA. Relative fold changes 
in mRNA were determined according to the ΔΔCt 
method, relative to the housekeeping gene 36B4, and 
intraexperimental standard deviation (s.d.) was calculated 
according to Bookout and Mangelsdorf [57]. Statistical 
significance was calculated from three independent 
experiments using Student’s t test.
Plasmids and transfections
Plasmids for β-catenin (pmT23 β-catenin) [58], 
pSM2c GSK-3α (αsh1 and αsh2), GSK-3β (βsh1 and 
βsh2) and control shRNA plasmid (Open Biosystems, 
Madrid, Spain) [59, 60], RelA, RelB and c-Rel shRNAs 
[35] (from B. Lewis (NCI, Bethesda, MA, USA) 
and pSUPER-Retro-puro control shRNA [61] (from 
A. Carracedo, CIC bioGUNE) were previously described. 
Gene reporter assays were carried out using NFκB-
luciferase (Clontech), pGal4, pGal4-p65 [62] and Gal4-
luciferase (from the BCCM/LMBP, Ghent University/
Lienhard Schmitz, Institute of Biochemistry, University 
of Giessen), pRL-TK (Promega), MMTV-luciferase (from 
C. Bevan, Imperial College London) and Super8xTOP/
FOPFlash [63] (from R. Moon, University of Washington, 
Seattle). Cells were plated at a density of 50,000 cells/cm2 
(22Rv1) or 25,000 cells/cm2 in 24-well plates and 24–48 
hours later transfected using 1 μl of Lipofectamine, 2 μl 
of Plus reagent, 100 ng of firefly luciferase reporter, 0.5 ng 
pGal4/pGal4-p65 (where indicated), 15 ng of pRL-TK 
and up to 200 ng (unless otherwise indicated) of shRNA 
or expression plasmids, according to manufacturer’s 
instructions (Invitrogen). Luciferase activity was measured 
with the DualGlo Stop&Glo luciferase assay system 
(Promega). For experiments using MMTV-luciferase, cells 
were cultured in phenol red-free RPMI and 10% charcoal-
stripped serum.
Transcription factor binding screen
Cells were rinsed in PBS and nuclear extracts were 
prepared using the Nuclear Extraction Kit (Panomics). 
5 μg of nuclear extract was used for hybridization with the 
TranSignal™ Protein/DNA Array I (Panomics), according 
to manufacturer’s instructions. In brief, nuclear extracts 
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were incubated with a pool of biotin-labeled transcription 
factor (TF) binding probes, and DNA/TF complexes 
were isolated using an ion-exchange column. Finally, 
the isolated DNA probes were hybridized to membranes 
containing complementary TF binding site sequences and 
bound probes were visualized using an HRP-conjugated 
anti-biotin antibody. Quantitation was done by selecting 
non-saturated exposures of high-resolution scans of the 
membranes, grid circles and calculating the average signal 
using ImageJ software, using negative controls as a blank 
and taking the average signal from the row of positive 
controls for each membrane to normalize the data for each 
membrane. Binding assay experiments were carried out at 
least twice each, and, in the case of the stable lines, using 
two different shRNAs for each GSK-3 isoform.
Western blotting
Cells were rinsed in PBS and lysed in RIPA 
(radioimmunoprecipitation assay) lysis buffer (19) 
containing Complete™ Protease Inhibitor Cocktail (Roche) 
and PhosSTOP Phosphatase Inhibitor Cocktail (Roche) 
on ice for 15 minutes, cleared by centrifugation and used 
directly or frozen on dry ice for later use. 20 μg of lysate 
was resolved on 8% or 10% SDS polyacrylamide gels, 
transferred to nitrocellulose membranes (Whatman). 
Nonspecific binding was blocked using 3% BSA/TBST 
(TBS with 0.05% Tween-20), and blots were probed 
overnight at 4ºC with primary antibodies. Blots were washed 
in TBST and antigens were detected using HRP-conjugated 
secondary antibodies as previously described [1, 59]. 
Primary antibodies, diluted 1:1000, were to GSK-3α (Santa 
Cruz Biotechnology sc-5264), GSK-3β (BD Biosciences 
610202), HSP60 (Santa Cruz Biotechnology), GAPDH 
(Sigma), and to NFkB p65 (D14E12), RelB (C1E4), c-Rel, 
p105/p50 and p100/p52 (18D10) (all Cell Signaling).
Immunofluorescence
Cells were plated on gelatin-coated glass coverslips 
48 h before transfection. Cells were fixed for 15 min in 4% 
PFA, permeabilized with 0.1% Triton for 10 min, incubated 
for 1 h with blocking buffer (50 mM glycine, 2% BSA, 
0.01% Na-azide in PBS) to block nonspecific binding and 
probed for 2 h with primary antibodies diluted in wash buffer 
(blocking buffer 1:10 in PBS). Primary antibodies used were 
to GSK-3α (1:500, Santa Cruz Biotechnology sc-5264), 
GSK-3β (1:500, BD Biosciences 610202), p65 (1:200, Santa 
Cruz Biotechnology) and p100/52 (1:250, Abcam). Immune 
complexes were detected with appropriate Alexa488- or 
Alexa594-congugated secondary antibodies (Invitrogen) 
diluted 1:500 in wash buffer and mounted using Vectashield® 
(Vector Labs), and DAPI (diamidino-2-phenylindole) was 
used to stain nuclei. Confocal images were acquired as 
previously described [59] with an SP2 microscope station 
(Leica) using a 63 x 1.3 NA lens.
Analysis of microarray data
The human prostate cancer gene expression 
datasets used (Becic [37]; Taylor [40]) are available 
at caArray (https://array.nci.nih.gov/caarray/home.
action) and cBio Cancer Genomics (www.cbioportal.
org/public-portal/), respectively. Cell files containing 
raw data were normalized with RMAExpress (Robust 
Multichip Average) software, and chips with normalized 
unscaled standard error (NUSE) or relative log expression 
(RLE) values 1.5 IQR (interquartile range) above the 
upper quartile or 1.5 IQR below the lower quartile 
were discarded in further analysis. The intensity of the 
androgen-responsive-gene signature [38] was then scored 
using the Z-score values calculated for the genes included 
in the signature, and those tumors with highest or lowest 
added Z-score were classified as high or low AR-signature, 
respectively. Similarly, the Z-score was calculated for 
GSK3A and GSK3B and tumors with a Z-score value 
of GSK3A and GSK3B > 0.5 were classified high total 
GSK3, and tumors with a Z-value < ˗0.5 for both isoforms 
were classified as low total GSK3. Gene set enrichment 
analysis (GSEA) [36] was performed with the normalized 
gene expression values from the tumors classified as above 
(high vs. low AR signature; high vs. low GSK3), and 
the level of enrichment of the NFκB signature [39] was 
calculated using Student’s t test on the collapsed probe sets 
and running 1000 permutations. Kaplan Meier plots were 
obtained from cBio Cancer Genomics portal analyzing 
the Michigan metastatic prostate adenocarcinoma dataset 
[41]. Statistical significance of the whole sample was 
determined with the log rank test both at 100 months and 
220 months, with the former found to be significant.
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